These data outline a sensitivity for MEK inhibition in mesenchymal neuroblastomas and that MAPK signaling might be linked to the mesenchymal phenotype and not any other molecular feature (Fig. 1A). This evidence concerns the gene MAP2K7 and neuroblastoma.